2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸 | 80709-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡咯
• 中文名称: 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸
• 中文别名: 2-甲基-4H-呋喃[3,2-B]吡咯-5-羧酸
• 英文名称: 2-methyl-4H-furo[3,2-b]pyrrole-5-carboxylic acid
• CAS: 80709-80-4
• 化学式: C₈H₇NO₃
• mdl: MFCD07403678
• 分子量: 165.148
• InChiKey: ILLLWINWDFYWES-UHFFFAOYSA-N

物化性质

• 熔点：
  168 °C(Solv: ethanol (64-17-5))
• 沸点：
  378.1±37.0 °C(Predicted)
• 密度：
  1.455±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  66.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸 在 三氟乙酸 作用下， 反应 0.17h， 生成 2-methyl-4H-furo[3,2-b]pyrrole
  参考文献：
  名称：

  可见光-近红外区域中明亮、颜色可调的荧光染料

  摘要：

  新合成的 Keio Fluors 基于硼-二吡咯亚甲基 (BDP)，具有出色且有用的光学特性：在可见光-近红外区域 (583-738 nm) 中呈现鲜艳的色彩和锐利的发射，高量子产率 (Φ: 0.56−0.98)、高消光系数 (185000−288000 M-1 cm-1) 和良好的光稳定性。这些光学特性优于许多现有的荧光染料，例如罗丹明、花青或其他基于 BDP 的荧光染料。

  DOI：

  10.1021/ja077756j
• 作为产物：
  描述：

  2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以83.7%的产率得到2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸
  参考文献：
  名称：

  可见光-近红外区域中明亮、颜色可调的荧光染料

  摘要：

  新合成的 Keio Fluors 基于硼-二吡咯亚甲基 (BDP)，具有出色且有用的光学特性：在可见光-近红外区域 (583-738 nm) 中呈现鲜艳的色彩和锐利的发射，高量子产率 (Φ: 0.56−0.98)、高消光系数 (185000−288000 M-1 cm-1) 和良好的光稳定性。这些光学特性优于许多现有的荧光染料，例如罗丹明、花青或其他基于 BDP 的荧光染料。

  DOI：

  10.1021/ja077756j

文献信息

• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE
  申请人：Heffernan L. R. Michele

  公开号：US20080004327A1

  公开（公告）日：2008-01-03

  This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR 1 and N. X and Y are members independently selected from O, S, CR 2 , N and NH. R 1 , R 2 and R 4 are members independently selected from H and F, provided that at least one member selected from R 1 , R 2 and R 4 is F. R 6 is a member selected from O − X + and OH, wherein X + is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

  这项发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病，如神经精神病和神经退行性疾病，以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构：其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员，前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员，其中X+是正离子，从无机正离子和有机正离子中选择的成员。
• Synthesis and antibacterial activity of furo[3,2-b]pyrrole derivatives
  作者：Ivana Zemanová、Renata Gašparová、Andrej Boháč、Tibor Maliar、Filip Kraic、Gabriela Addová

  DOI：10.24820/ark.5550190.p010.240

  日期：——

  synthesized by reaction of appropriate triazinone with POCl3 and subsequent treating of 8-chloro derivative with sodium ethoxide in ethanol. Furo[3,2-b]pyrrole-5carboxylates were hydrolysed to form acids, which underwent one-pot decarboxylation with TFA and formylation of the in situ formed furo[3,2-b]pyrrole with triethyl orthoformate to give 5-carbaldehydes. Hydrazinolysis of bis-esters led to bis-carbohydrazides

  8-乙氧基呋喃[2',3':4,5]吡咯并[1,2-d][1,2,4]三嗪通过适当的三嗪酮与POCl3反应，然后用乙醇钠处理8-氯衍生物合成在乙醇中。Furo[3,2-b]pyrrole-5carboxylates 水解形成酸，用 TFA 进行一锅脱羧，原位形成的 furo[3,2-b]pyrrole 与原甲酸三乙酯甲酰化得到 5-甲醛。双酯的肼解导致双碳酰肼，其随后在微波辐射下在乙酸中环化以形成具有不寻常手性的吡嗪或乙酰胺衍生物。评价制备的化合物对大肠杆菌和藤黄微球菌的抗菌活性。
• Tetrazole compounds as thyroid receptor ligands
  申请人：——

  公开号：US20020006946A1

  公开（公告）日：2002-01-17

  The present invention relates to tetrazole compounds of Formula I, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs. 1 The invention also relates to compositions comprising the tetrazole compounds and to methods of treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, and osteoporosis using the tetrazole compounds.

  本发明涉及公式I的四唑化合物、立体异构体、药用可接受的盐及其前药，以及前药的药用可接受的盐。该发明还涉及包含四唑化合物的组合物，以及使用四唑化合物治疗肥胖、糖尿病、动脉粥样硬化、高血压、冠心病、高胆固醇血症、高脂血症、甲状腺疾病、甲状腺癌、甲状腺功能减退症、抑郁症、青光眼、心律失常、充血性心力衰竭和骨质疏松症的方法。
• Development of UV-Excitable Red and Near-Infrared Fluorescent Labels and Their Application for Simultaneous Multicolor Bioimaging by Single-Wavelength Excitation
  作者：Tetsuya Mizuno、Keitaro Umezawa、Yutaka Shindo、Daniel Citterio、Kotaro Oka、Koji Suzuki

  DOI：10.1007/s10895-013-1227-5

  日期：2013.9

  We report a new type of UV-excitable red/NIR-emissive fluorescent dyads (PKF series). Conjugation of a pyrene and a novel bright red/near-infrared (NIR) fluorophore resulted in large quasi-Stokes shift while retaining intense fluorescence emission and sharp spectral bands. Labeling of PKF dyads to biomolecules was performed by means of introduction of a succinimidyl ester. Simultaneous Ca2+/albumin dual-color intracellular imaging by PKF in combination with fura-2 (UV-excitable/VIS-emissive Ca2+ indicator) reveals its usefulness as a new bioimaging tool.

  我们报告了一种新型紫外可激发红色/近红外可激发荧光二元体（PKF 系列）。芘和新型亮红/近红外（NIR）荧光团的共轭产生了较大的准斯托克斯位移，同时保留了强烈的荧光发射和清晰的光谱带。通过引入琥珀酰亚胺酯，将 PKF 二聚体标记到生物大分子上。PKF 与 fura-2（紫外可激发/可见光可激发 Ca2+ 指示剂）结合使用，可同时进行 Ca2+/ 白蛋白双色细胞内成像，这揭示了 PKF 作为一种新型生物成像工具的实用性。